Report Published: "Zimbabwe Pharmaceuticals & Healthcare Report Q1 2016"

Although the government's ambition to develop a national health insurance scheme to facilitate universal health coverage is a positive step, Zimbabwe's healthcare system , in its current state, is heavily dependent on donor funds, owing to past failures to sufficiently finance its health sector. Global recession is presenting a significant risk as the availability of funds from foreign organisation s dries up. Political instability and a grim economic outlook enforce our view that Zimbabwe will remain an unattractive market for multinational drugmakers.

Headline Expenditure Projections

Pharmaceuticals: USD361mn in 2014 to USD380mn in 2015; +5.2% in US dollar terms. Forecast unchanged from last quarter .

Risk/Reward Index

In BMI's Risk/Reward Index for Q116, Zimbabwe scores 25.3 out of 100, down from last quarter's score of 27.8. The country is ranked 29th out of the 31 markets surveyed in the Middle East and Africa (MEA) region, just below Nigeria (26.0) and above Uganda (24.7). Zimbabwe will remain one of the least-attractive pharmaceutical and healthcare markets regionally and globally, due to the elevated political, economic and social risks, as well as the lack of finances for adequate healthcare provision and capacity utilisation.

Full Report Details at
- http://www.fastmr.com/prod/1109989_zimbabwe_pharmaceuticals.aspx?afid=301

Recent Developments

In October 2015, the Cancer Association of Zimbabwe (CAZ) carried out a free breast cancer screening programme in Harare as part of World Cancer month commemorations.

The Zimbabwe Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Zimbabwe Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Zimbabwe pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Zimbabwe, to test other views - a key input for successful budgeting and strategic business planning in the Zimbabwean pharmaceutical and healthcare market.
* Target business opportunities and risks in the Zimbabwean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Zimbabwe.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- France Pharmaceuticals & Healthcare Report Q1 2016
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016